Abstract Library

#4570 Diagnosis of carcinoid heart disease continues to be late delayed

Introduction: Carcinoid heart disease (CHD) is a serious complication of neuroendocrine tumours. It affects patients with carcinoid syndrome and results from fibrotic deposits on the heart valves. It significantly impacts patient prognosis.

Conference:

Presenting Author:

Authors: Sharma J, Shah T, Coldham C, Vickrage S, Rehman Z,

Keywords: carcinoid syndrome, neuroendocrine tumour, carcinoid heart disease, symptoms, presentation, echocardiogram, heart valves,

#4537 The usefulness of circulating fibrosis markers in detection of carcinoid heart disease

Introduction: Carcinoid heart disease (CHD) is a potential serious fibrotic complication in patients with neuroendocrine neoplasms (NENs), affecting the heart valves. Early detection is crucial to avoid severe manifestations. NT-proBNP is suggested as an initial screening tool in detection of CHD; however, the value of NT-proBNP as a screening tool is questionable.

Conference:

Presenting Author: Lau T

Authors: Lau T, Angeli E, Oksjoki R, Rasmussen V, Genovese F,

Keywords: carcinoid heart disease, biomarker, fibrosis marker,

#4152 Valvular surgery in carcinoid heart disease – Indications and outcome

Introduction: Neuroendocrine tumors (NET) can release biogenic amines that can induce a fibrotic process in the heart valves known as carcinoid heart disease (CHD). Valvular replacement surgery is the standard of care, but such interventions are associated with significant morbidity and valid criteria for both selecting patients (pts) and timing of surgery are limited.

Conference:

Presenting Author:

Authors: Sponheim J, Beitnes J, Dahle G, Åvitsland T, Thiis-Evensen E,

Keywords: carcinoid heart disease, valvular surgery, prognostic factors,

#2833 Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels

Introduction: Neuroendocrine tumours of the gastrointestinal tract cause carcinoid syndrome and carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and valve incompetence. Most cases involve the tricuspid valve +/- pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve replacement surgery which improves exercise tolerance but has high perioperative mortality. We have previously reported that valve-replacement surgery can reduce 5-hydroxyindoleacetic acid (5-HIAA) levels, reflecting a decline in hormone activity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Shah H

Authors: Shah H, Sagar V, Venkataraman H, Steeds R, Rooney S,

Keywords: carcinoid, carcinoid syndrome, neuroendocrine tumour, carcinoid heart disease, 5hiaa,

#2260 Carcinoid Heart Failure in a Metastatic Duodenal Neuroendocrine Tumor: A Challenging Case Report.

Introduction: Carcinoid heart disease (CHD) is a potenzial fatal cardiac manifestation, characterized by fibrous endocardial thickening involving right-sided heart valves. In 70% of cases, CHD occurs in advanced small bowel NETs with carcinoid syndrome (CS). Serotonin seems to play a main role. Early recognition and surgical intervention may improve the outcome of patients.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Brizzi M

Authors: Brizzi M, La Salvia A, Parisi F, Scagliotti G,

Keywords: Carcinoid Hearth Disease, Carcinoid syndrome, Surgery, somatostatin analogues,